Improving the bioavailability and solubility of modern active pharmaceutical ingredients (APIs) remains a critical challenge in drug development. As the industry shifts towards highly lipophilic, poorly water-soluble compounds, particularly BCS Class II and IV, formulators are increasingly adopting advanced materials and computational tools to enhance therapeutic performance. Gloria Ho, PharmD, RPh, Global Technical Marketing Manager at BASF, emphasizes the need for a multifaceted approach that combines experimental techniques with predictive modeling to navigate these complexities effectively.
Automation and technology advancements, including small-scale preparative techniques and formulation screening strategies, are essential for early development success. Craig Grant, Vice President and General Manager at Cambridge, Veranova, notes that integrating these methods can help identify critical solubility and dissolution properties, addressing potential developability issues sooner and conserving valuable resources. The synergy between experimental validation and computational insights is reshaping the landscape, enabling formulators to pinpoint the most viable enhancement pathways for drug candidates.
Get started today with Solo access →
